Download PDF
Journal of Pediatric Epilepsy 2023; 12(04): 122-129
DOI: 10.1055/s-0043-1764390
Original Article

Clinical Characteristics and Prognosis of Juvenile Myoclonic Epilepsy: Single-Center Retrospective Study

Tamer Çelik 
1   Division of Pediatric Neurology, Department of Pediatrics, Sağlık Bilimleri University, Adana Şehir Research and Training Hospital, Adana, Türkiye
,
Hüseyin Başpınar 
2   Department of Pediatrics, Pediatrician, Şanlıurfa Research and Training Hospital, Şanlıurfa, Türkiye
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Juvenile myoclonic epilepsy (JME) is one of the most common idiopathic (genetic) generalized epilepsy syndromes. It occurs in healthy adolescents and is characterized by the triad of myoclonic jerks, generalized tonic-clonic seizures (GTCs), and absence seizures. The study's primary aim was to determine the demographic and clinical characteristics, family history of seizure, electroencephalogram findings, treatments, and short-term prognosis of patients diagnosed with JME. Patients diagnosed with JME at the Pediatric Neurology Department of Sağlık Bilimleri University Adana Numune Training and Research Hospitals were enrolled. Thirteen (30%) of 44 patients were male, whereas 31 (70%) were female, with a mean age at diagnosis of 14 ± 1.3 years. In total, 21 patients (48%) had a family history of epilepsy, and 14 patients (32%) had JME in their families. Those having a family history of JME seizures were identified at a younger age. Thirty (68%) patients presented with GTCs, while 14 (32%) presented with myoclonic seizures at the time of diagnosis. In the history, 98% of patients had myoclonus and one patient had an absence seizure. Patients with the first seizure type GTCs were diagnosed later, while patients with myoclonus were diagnosed earlier (p < 0,05). The most precipitating factors for seizures were sleep deprivation and stress. Thirty-eight (86%) of the EEGs recorded during the initial admission was abnormal. Valproic acid was administered to 32 patients (73%), while levetiracetam was administered to 12 patients (27%) as the initial treatment. Forty-one (93%) of the patients exhibited a complete response to the initial medication therapy, while forty (91%) of the patients received monotherapy, and only four (9%) received polytherapy. JME may be well-controlled epilepsy with early diagnosis and appropriate treatment. A family history of JME is also common among patients with JME. Patients with the myoclonus as a first seizure type are diagnosed earlier than GTCs because of family awareness. A family history of JME may facilitate the diagnosis of new cases in the family.

Keywords

juvenile myoclonic epilepsy - seizures - myoclonus


Publication History

Received: 21 December 2022

Accepted: 05 February 2023

Article published online:
31 March 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Korff CM. Juvenile myoclonic epilepsy. Accessed April 18, 2022 at: www.uptodate.com
    PubMedGoogle Scholar
  • 2 Camfield CS, Striano P, Camfield PR. Epidemiology of juvenile myoclonic epilepsy. Epilepsy Behav 2013; 28 (Suppl. 01) S15-S17
    CrossrefPubMedGoogle Scholar
  • 3 Najafi MR, Najafi MA, Safaei A. Association of family history of epilepsy with earlier age onset of juvenile myoclonic epilepsy. Iran J Child Neurol 2016; 10 (02) 10-15
    PubMedGoogle Scholar
  • 4 Zifkin B, Andermann E, Andermann F. Mechanisms, genetics, and pathogenesis of juvenile myoclonic epilepsy. Curr Opin Neurol 2005; 18 (02) 147-153
    CrossrefPubMedGoogle Scholar
  • 5 Delgado-Escueta AV, Koeleman BP, Bailey JN, Medina MT, Durón RM. The quest for juvenile myoclonic epilepsy genes. Epilepsy Behav 2013; 28 (Suppl. 01) S52-S57
    CrossrefPubMedGoogle Scholar
  • 6 Bailey JN, de Nijs L, Bai D. et al. Variant intestinal-cell kinase in juvenile myoclonic epilepsy. N Engl J Med 2018; 378 (11) 1018-1028
    CrossrefPubMedGoogle Scholar
  • 7 Genç F, Kara M, Ünal Y. et al. Methylation of cation-chloride cotransporters NKCC1 and KCC2 in patients with juvenile myoclonic epilepsy. Neurol Sci 2019; 40 (05) 1007-1013
    CrossrefPubMedGoogle Scholar
  • 8 Baykan B, Wolf P. Juvenile myoclonic epilepsy as a spectrum disorder: a focused review. Seizure 2017; 49: 36-41
    CrossrefPubMedGoogle Scholar
  • 9 Atakli D, Senadim S, Baslo SA, Güveli BT, Daryan MD, Sari H. Misdiagnosis in JME: still a problem after 17 years?. Seizure 2016; 36: 27-30
    CrossrefPubMedGoogle Scholar
  • 10 Chawla T, Chaudhry N, Puri V. Cognitive dysfunction in juvenile myoclonic epilepsy—a tertiary care center study. Ann Indian Acad Neurol 2021; 24 (01) 40-50
    CrossrefPubMedGoogle Scholar
  • 11 Hashemiaghdam A, Sharifi A, Miri M, Tafakhori A. Seizure-control effect of levetiracetam on juvenile myoclonic epilepsy and other epileptic syndromes: a literature review of recent studies. Iran J Child Neurol 2015; 9 (02) 1-8
    PubMedGoogle Scholar
  • 12 Dervent A, Ayşen Gökyiğit A. Çocukluk ve ergenlikte başlayan idiopatik jeneralize epilepsiler. Epilepsi 2014; 20 (01) 13-22
    PubMedGoogle Scholar
  • 13 Höfler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Seizure outcome in 175 patients with juvenile myoclonic epilepsy—a long-term observational study. Epilepsy Res 2014; 108 (10) 1817-1824
    CrossrefPubMedGoogle Scholar
  • 14 Dhanuka AK, Jain BK, Daljit S, Maheshwari D. Juvenile myoclonic epilepsy: a clinical and sleep EEG study. Seizure 2001; 10 (05) 374-378
    CrossrefPubMedGoogle Scholar
  • 15 Serdaroğlu G, Tekgül H. Çocukluk çağı ve adölesan dönemi İdyopatik Epilepsileri. In: Gökçay E, Sönmez FM, Topaloğlu H, Tekgül H, Gürer Y. (Eds) Çocuk Nörolojisi 2. Baskı Türk Çocuk Nörolojisi Derneği; 2010. 8: 297-308
    Google Scholar
  • 16 Cvetkovska E, Panov S, Kuzmanovski I. Clinical genetic study in juvenile myoclonic epilepsy. Seizure 2014; 23 (10) 903-905
    CrossrefPubMedGoogle Scholar
  • 17 Kleveland G, Engelsen BA. Juvenile myoclonic epilepsy: clinical characteristics, treatment and prognosis in a Norwegian population of patients. Seizure 1998; 7 (01) 31-38
    CrossrefPubMedGoogle Scholar
  • 18 da Silva Sousa P, Lin K, Garzon E, Sakamoto AC, Yacubian EM. Self-perception of factors that precipitate or inhibit seizures in juvenile myoclonic epilepsy. Seizure 2005; 14 (05) 340-346
    CrossrefPubMedGoogle Scholar
  • 19 Canevini MP, Mai R, Di Marco C. et al. Juvenile myoclonic epilepsy of Janz: clinical observations in 60 patients. Seizure 1992; 1 (04) 291-298
    CrossrefPubMedGoogle Scholar
  • 20 Shahnaz SK, Sher K, Abdul Sattar R. Clinical and EEG characteristics of juvenile myoclonic epilepsy. Pak J Med Sci 2014; 30 (01) 12-15
    PubMedGoogle Scholar
  • 21 Ryasi HR, Taheri MMH, Rezvani MR, Nakhaei F, Salehi F. Clinical evaluation of 32 patients with juvenile myoclonic epilepsy in Southern Khorasan. Iran J Neurol 2008; 7 (23) 290-296
    PubMedGoogle Scholar
  • 22 Motamedi M, Mohammad Ali S, Rahmat M. Comparison of valporic acid efficacy in familial versus sporadic cases of juvenile myoclonic epilepsy. Neurol India 2006; 54 (02) 186-189 , discussion 189
    PubMedGoogle Scholar
  • 23 Murthy JMK, Rao CM, Meena AK. Clinical observations of juvenile myoclonic epilepsy in 131 patients: a study in South India. Seizure 1998; 7 (01) 43-47
    CrossrefPubMedGoogle Scholar
  • 24 Bingel A. Reading epilepsy. Neurology 1957; 7 (11) 752-756
    CrossrefPubMedGoogle Scholar
  • 25 Rushton DN. “Space invader” epilepsy. Lancet 1981; 1 (8218): 501
    PubMedGoogle Scholar
  • 26 Ferrie CD, De Marco P, Grünewald RA, Giannakodimos S, Panayiotopoulos CP. Video game induced seizures. J Neurol Neurosurg Psychiatry 1994; 57 (08) 925-931
    CrossrefPubMedGoogle Scholar
  • 27 Fylan F, Harding GFA, Edson AS, Webb RM. Mechanisms of video-game epilepsy. Epilepsia 1999; 40 (Suppl. 04) 28-30
    CrossrefPubMedGoogle Scholar
  • 28 Harding GFA, Jeavons PM, Edson AS. Video material and epilepsy. Epilepsia 1994; 35 (06) 1208-1216
    CrossrefPubMedGoogle Scholar
  • 29 Kasteleijn-Nolst Trenité DGA. Video-game epilepsy. Lancet 1994; 344 (8930): 1102-1103
    CrossrefPubMedGoogle Scholar
  • 30 Badinand-Hubert N, Bureau M, Hirsch E. et al. Epilepsies and video games: results of a multicentric study. Electroencephalogr Clin Neurophysiol 1998; 107 (06) 422-427
    CrossrefPubMedGoogle Scholar
  • 31 Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Paediatr Drugs 2001; 3 (05) 379-403
    CrossrefPubMedGoogle Scholar
  • 32 Jayalakshmi SS, Srinivasa Rao B, Sailaja S. Focal clinical and electroencephalographic features in patients with juvenile myoclonic epilepsy. Acta Neurol Scand 2010; 122 (02) 115-123
    PubMedGoogle Scholar
  • 33 Vijai J, Cherian PJ, Stlaja PN, Anand A, Radhakrishnan K. Clinical characteristics of a South Indian cohort of juvenile myoclonic epilepsy probands. Seizure 2003; 12 (07) 490-496
    CrossrefPubMedGoogle Scholar
  • 34 Manonmani V, Tan CT. Juvenile myoclonic epilepsy—a report of 11 patients at the University Hospital, Kuala Lumpur. Singapore Med J 1993; 34 (05) 378-380
    PubMedGoogle Scholar
  • 35 Gunatilake SB, Seneviratne SL. Juvenile myoclonic epilepsy: a study in Sri Lanka. Seizure 2000; 9 (03) 221-223
    CrossrefPubMedGoogle Scholar
  • 36 Mehndiratta MM, Aggarwal P. Clinical expression and EEG features of patients with juvenile myoclonic epilepsy (JME) from North India. Seizure 2002; 11 (07) 431-436
    CrossrefPubMedGoogle Scholar
  • 37 Çelik Y, Karaağaç N, Yeni S, Ergin N. Juvenil miyoklonik epilepsili hastaların klinik ve elektroensefalografik değerlendirilmesi. Epilepsi 2001; 7 (03) 84-88
    PubMedGoogle Scholar
  • 38 Ertem DH, Yalaz Tekan Ü, Polat F, Gökçal E. Van ilinde juvenil miyoklonik epilepsinin geç tanı alma nedenleri. Epilepsi 2014; 20 (03) 117-120
    PubMedGoogle Scholar
  • 39 Asadi-Pooya AA, Hashemzehi Z, Emami M. Epidemiology and clinical manifestations of juvenile myoclonic epilepsy (JME) in Iran. Neurol Sci 2015; 36 (05) 713-716
    CrossrefPubMedGoogle Scholar
  • 40 Specchio N, Boero G, Michelucci R. et al. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy. Epilepsia 2008; 49 (04) 663-669
    CrossrefPubMedGoogle Scholar
  • 41 Jain S, Tripathi M, Srivastava AK, Narula A. Phenotypic analysis of juvenile myoclonic epilepsy in Indian families. Acta Neurol Scand 2003; 107 (05) 356-362
    CrossrefPubMedGoogle Scholar
  • 42 Koepp MJ, Woermann F, Savic I, Wandschneider B. Juvenile myoclonic epilepsy–neuroimaging findings. Epilepsy Behav 2013; 28 (Suppl. 01) S40-S44
    CrossrefPubMedGoogle Scholar
  • 43 Anderson J, Hamandi K. Understanding juvenile myoclonic epilepsy: contributions from neuroimaging. Epilepsy Res 2011; 94 (03) 127-137
    CrossrefPubMedGoogle Scholar
  • 44 Szabó CA, Salinas FS. Voxel-based morphometry in epileptic baboons: Parallels to human juvenile myoclonic epilepsy. Epilepsy Res 2016; 124: 34-39
    CrossrefPubMedGoogle Scholar
  • 45 Lin K, de Araujo Filho GM, Pascalicchio TF. et al. Hippocampal atrophy and memory dysfunction in patients with juvenile myoclonic epilepsy. Epilepsy Behav 2013; 29 (01) 247-251
    CrossrefPubMedGoogle Scholar
  • 46 Marson AG, Al-Kharusi AM, Alwaidh M. et al; SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369 (9566): 1016-1026
    CrossrefPubMedGoogle Scholar
  • 47 Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol 2016; 15 (02) 210-218
    CrossrefPubMedGoogle Scholar
  • 48 Mehmood T, Saleem M, Shah SSH. Frequency of valproate-induced thrombocytopenia in epileptic children. JUMDC 2014; 5 (02) 52-56
    PubMedGoogle Scholar